Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
30.05. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
20.05. | ZyVersa's IC 100 shows promise in Parkinson's treatment | 5 | Investing.com | ||
20.05. | ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson's and Alzheimer's Diseases | 118 | GlobeNewswire (Europe) | Study results corroborate our recently published data demonstrating the critical role of microglial-driven inflammation in promoting accumulation and spread of toxic phosphorylated alpha-synuclein... ► Artikel lesen | |
13.05. | ZyVersa Therapeutics GAAP EPS of -$0.73 | 3 | Seeking Alpha | ||
12.05. | ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress | 135 | GlobeNewswire (Europe) | KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease... ► Artikel lesen | |
12.05. | ZyVersa Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
07.05. | ZyVersa progresses with obesity inflammation treatment | 9 | Investing.com | ||
ZYVERSA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
07.05. | ZyVersa Therapeutics: ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update | 3 | GlobeNewswire (USA) | ||
29.04. | ZyVersa Therapeutics Publishes Data Supporting Potential Of Its Inflammasome ASC Inhibitor IC 100 | 1 | RTTNews | ||
29.04. | ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson's Disease | 4 | GlobeNewswire (USA) | ||
24.04. | ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development Status | 61 | GlobeNewswire (Europe) | WESTON, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment... ► Artikel lesen | |
10.04. | Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday? | 2 | Insider Monkey | ||
08.04. | ZyVersa CEO outlines progress in kidney disease drug development | 4 | Investing.com | ||
08.04. | ZyVersa-CEO erläutert Fortschritte bei der Entwicklung von Medikamenten gegen Nierenerkrankungen | 4 | Investing.com Deutsch | ||
08.04. | ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) | 169 | GlobeNewswire (Europe) | WESTON, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment... ► Artikel lesen | |
07.04. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
04.04. | ZyVersa Therapeutics files to sell 4.21M shares of common stock by selling shareholders | 1 | Seeking Alpha | ||
27.03. | ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update | 184 | GlobeNewswire (Europe) | KEY HIGHLIGHTS: Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease (DKD) expected to begin H1-2025. Regulatory path for VAR... ► Artikel lesen | |
27.03. | ZyVersa Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 92,00 | -0,22 % | BioNTech, Moderna und Co im Fokus: Kennedy greift durch | Nächster Paukenschlag in den USA: Gesundheitsminister Robert F. Kennedy Jr. hat alle Mitglieder eines Gremiums (ACIP) von Impfexperten der US- Seuchenbehörde CDC entlassen. Das geht aus einer Mitteilung... ► Artikel lesen | |
QIAGEN | 40,680 | -0,01 % | Qiagen NV-Aktie gewinnt 1,15 Prozent (40,805 €) | Im Wertpapierhandel liegt die Aktie von Qiagen NV gegenwärtig im Plus. Das Wertpapier kostete zuletzt 40,81 Euro. Für die Aktie von Qiagen NV steht gegenwärtig ein Wertanstieg 1,15 Prozent zu Buche.... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,920 | -4,84 % | HotStocks USA: TESLA, NVIDIA und RECURSION PHARMA stark gehandelt | ||
CUREVAC | 4,848 | +0,46 % | Mega-Deal in der Biotech-Branche: BioNTech greift nach CureVac! | In einer wegweisenden Branchenfusion übernimmt BioNTech SE (Nasdaq: BNTX), Pionier der mRNA-Technologie und bekannt durch den COVID-19-Impfstoff, das deutsche Biotech-Unternehmen CureVac N.V. (Nasdaq:... ► Artikel lesen | |
EVOTEC | 7,398 | -2,66 % | Aktie von Evotec legt um 2,55 Prozent zu (7,24 €) | An der deutschen Börse liegt die Aktie von Evotec derzeit im Plus. Der jüngste Kurs betrug 7,24 Euro. Ein Preisanstieg von 2,55 Prozent steht gegenwärtig für der Anteilsschein von Evotec zu Buche. Das... ► Artikel lesen | |
DYNE THERAPEUTICS | 14,410 | -0,35 % | Dyne Therapeutics, Inc. Q1 Loss Increases, Misses Estimates | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) revealed Loss for its first quarter that increased from last year and missed the Street estimates.The company's earnings came in at -$115.361... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 31,370 | -2,40 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 46,780 | +0,04 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
ARS PHARMACEUTICALS | 15,390 | +6,88 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates | $7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing... ► Artikel lesen | |
MODERNA | 23,180 | -1,19 % | Zukunftsmarkt - hier geht es um 50 Mrd. USD: Illumina, Moderna, PanGenomic Health | Medizin wird persönlich. Die Zeit, in der Medikamente allen helfen sollen, naht ihrem Ende. Die Experten von BCC Research gehen davon aus, dass der Markt für personalisierte Medizin zwischen 2023 und... ► Artikel lesen | |
APOGEE THERAPEUTICS | 44,450 | +6,16 % | Apogee Therapeutics stock maintains buy rating ahead of key trial data | ||
ENLIVEN THERAPEUTICS | 21,910 | +11,47 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
ADMA BIOLOGICS | 20,820 | -3,61 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 19,780 | -1,88 % | Why Summit Therapeutics Stock Tanked Today | ||
TANGO THERAPEUTICS | 4,690 | -7,13 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors | BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines... ► Artikel lesen |